返回 
加入收藏
高剂量艾普拉唑联合阿莫西林用于老年新发幽门螺杆菌感染患者的临床研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 高剂量艾普拉唑联合阿莫西林用于老年新发幽门螺杆菌感染患者的临床研究 |
| TITLE： | Clinical study on high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with Helicobacter pylori infection |
| 摘要： | 目的 评价高剂量艾普拉唑联合阿莫西林用于老年新发幽门螺杆菌（Hp）感染患者的疗效及安全性，分析Hp感染根除治疗失败的独立危险因素。方法选取2021年8月1日至2024年12月1日就诊于新乡市中心医院的200例老年新发Hp感染患者，按随机数字表法分为对照组和研究组，每组各100例。对照组患者给予经典四联方案（阿莫西林胶囊+克拉霉素片+枸橼酸铋钾片+艾普拉唑肠溶片），研究组患者给予高剂量艾普拉唑肠溶片+阿莫西林胶囊，所有患者均用药2周。比较意向性治疗（ITT）、方案治疗（PP）分析集中两组患者的Hp根除率，记录两组患者的不良反应发生情况；采用多因素Logistic回归分析筛选影响Hp感染根除治疗失败的独立危险因素。结果ITT及PP分析集中，两组患者的Hp根除率比较，差异均无统计学意义（P＞0.05）。两组患者的轻、中度不良反应发生率比较，差异均无统计学意义（P＞0.05）。体重指数（BMI）≤18.5kg/m2、BMI＞23.9kg/m2、农村居住、合并糖尿病及合并心脏病经分析确定为影响Hp感染根除治疗失败的独立危险因素（P＜0.05）。结论高剂量艾普拉唑联合阿莫西林用于老年新发Hp感染患者的疗效和安全性均与经典四联方案相当。BMI≤18.5kg/m2、BMI＞23.9kg/m2、农村居住、合并糖尿病及合并心脏病是Hp感染根除治疗失败的独立危险因素。 |
| ABSTRACT： | OBJECTIVE To evaluate the efficacy and safety of high-dose ilaprazole combined with amoxicillin for newly diagnosed elderly patients with Helicobacter pylori （Hp） infection， and analyze independent risk factors for failure of Hp infection eradication treatment. METHODS Totally 200 cases of newly diagnosed elderly patients with Hp infection in Xinxiang Central Hospital from August 1， 2021 to December 1， 2024 were selected and randomly divided into control group and study group， with 100 cases in each group. The control group was treated with classic quadruple therapy regimen （Amoxicillin capsules+ Clarithromycin tablets+Bismuth potassium citrate tablets+Ilaprazole enteric-coated tablets）. The study group was treated with high- dose Ilaprazole enteric-coated tablets+Amoxicillin capsules. All patients were administered medication for 2 weeks. Hp eradication rates in the two groups were compared using intention-to-treat （ITT） and per-protocol （PP） analyses. The incidence of adverse reactions in both groups was also recorded. The multiple-factor Logistic regression analysis was used to identify independent risk factors for failure of Hp infection eradication treatment. RESULTS In ITT and PP analyses， there was no significant difference of Hp eradication rates between the two groups （P＞0.05）. There was no significant difference in incidence of mild to moderate adverse reactions between the two groups （P＞0.05）. BMI ≤18.5 kg/m2， BMI ＞23.9 kg/m2， rural residence， concomitant diabetes and concomitant heart disease were identified as independent risk factors influencing the failure of Hp infection eradication treatment （P＜0.05）. CONCLUSIONS The efficacy and safety of high-dose ilaprazole combined with amoxicillin are comparable to classic quadruple therapy regimen in treating newly diagnosed elderly patients with Hp infection. Independent risk factors influencing the failure of Hp infection eradication treatment include BMI ≤18.5 kg/m2， BMI ＞23.9 kg/m2， rural residence， concomitant diabetes and concomitant heart disease. |
| 期刊： | 2025年第36卷第14期 |
| 作者： | 李辰；王玉静；毛建娜；郭皓；沈裕厚；董志超；闫彬彬 |
| AUTHORS： | LI Chen，WANG Yujing，MAO Jianna，GUO Hao，SHEN Yuhou，DONG Zhichao，YAN Binbin |
| 关键字： | 幽门螺杆菌；高剂量二联疗法；艾普拉唑；阿莫西林；意向性治疗；方案治疗；老年患者 |
| KEYWORDS： | Helicobacter pylori； high-dose dual therapy； |
| 阅读数： | 9 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
